Raymond James Financial Inc. Buys Shares of 131,505 Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Raymond James Financial Inc. purchased a new position in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 131,505 shares of the company's stock, valued at approximately $746,000. Raymond James Financial Inc. owned about 0.24% of Voyager Therapeutics as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of VYGR. Barclays PLC raised its position in shares of Voyager Therapeutics by 55.8% in the third quarter. Barclays PLC now owns 104,462 shares of the company's stock valued at $612,000 after purchasing an additional 37,398 shares during the period. SG Americas Securities LLC lifted its position in Voyager Therapeutics by 86.7% during the 4th quarter. SG Americas Securities LLC now owns 23,044 shares of the company's stock worth $131,000 after acquiring an additional 10,704 shares during the last quarter. Empowered Funds LLC boosted its holdings in Voyager Therapeutics by 5.3% during the fourth quarter. Empowered Funds LLC now owns 47,206 shares of the company's stock valued at $268,000 after acquiring an additional 2,397 shares during the period. Allspring Global Investments Holdings LLC grew its position in shares of Voyager Therapeutics by 23.9% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 39,313 shares of the company's stock valued at $223,000 after purchasing an additional 7,573 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in shares of Voyager Therapeutics by 3.4% in the fourth quarter. Rhumbline Advisers now owns 71,497 shares of the company's stock worth $405,000 after purchasing an additional 2,354 shares during the period. 48.03% of the stock is currently owned by institutional investors.

Voyager Therapeutics Stock Performance

Shares of NASDAQ VYGR traded down $0.19 during midday trading on Friday, reaching $3.24. 756,113 shares of the company traded hands, compared to its average volume of 445,858. The firm has a market cap of $179.21 million, a PE ratio of 4.56 and a beta of 0.95. Voyager Therapeutics, Inc. has a 12 month low of $2.75 and a 12 month high of $9.55. The stock's 50-day simple moving average is $3.52 and its 200-day simple moving average is $4.92.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.18). Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The business had revenue of $6.47 million during the quarter, compared to analyst estimates of $13.55 million. On average, equities research analysts expect that Voyager Therapeutics, Inc. will post -0.91 EPS for the current year.

Insider Activity at Voyager Therapeutics

In related news, CEO Alfred Sandrock sold 10,885 shares of the business's stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $3.43, for a total value of $37,335.55. Following the completion of the transaction, the chief executive officer now owns 430,931 shares in the company, valued at $1,478,093.33. The trade was a 2.46 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 6.39% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

VYGR has been the topic of a number of research analyst reports. Wedbush reaffirmed an "outperform" rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of Voyager Therapeutics in a research report on Tuesday, April 8th. Cantor Fitzgerald reissued an "overweight" rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. Canaccord Genuity Group decreased their price target on shares of Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating on the stock in a research report on Thursday, March 13th. Finally, Wells Fargo & Company set a $10.00 price objective on shares of Voyager Therapeutics and gave the company an "overweight" rating in a research report on Wednesday, March 12th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Voyager Therapeutics has a consensus rating of "Buy" and an average price target of $13.97.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.